Literature DB >> 30120162

In Reply.

Chau T Dang1, Jasmeet C Singh1, Richard M Steingart2, Anthony F Yu2.   

Abstract

Mesh：

Year:  2018        PMID： 30120162      PMCID： PMC6292538          DOI： 10.1634/theoncologist.2018-0101

Source DB:  PubMed          Journal:  Oncologist        ISSN： 1083-7159


× No keyword cloud information.
  11 in total

1.  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Authors:  José Baselga; Javier Cortés; Sung-Bae Kim; Seock-Ah Im; Roberto Hegg; Young-Hyuck Im; Laslo Roman; José Luiz Pedrini; Tadeusz Pienkowski; Adam Knott; Emma Clark; Mark C Benyunes; Graham Ross; Sandra M Swain
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Authors:  David Cameron; Martine J Piccart-Gebhart; Richard D Gelber; Marion Procter; Aron Goldhirsch; Evandro de Azambuja; Gilberto Castro; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Nedal Al-Sakaff; Sabine Lauer; Eleanor McFadden; Brian Leyland-Jones; Richard Bell; Mitch Dowsett; Christian Jackisch
Journal:  Lancet       Date:  2017-02-17       Impact factor: 79.321

3.  Long-Term Cardiac Safety Analysis of NCCTG N9831 (Alliance) Adjuvant Trastuzumab Trial.

Authors:  Pooja P Advani; Karla V Ballman; Travis J Dockter; Gerardo Colon-Otero; Edith A Perez
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

4.  Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831.

Authors:  Edith A Perez; Edward H Romond; Vera J Suman; Jong-Hyeon Jeong; George Sledge; Charles E Geyer; Silvana Martino; Priya Rastogi; Julie Gralow; Sandra M Swain; Eric P Winer; Gerardo Colon-Otero; Nancy E Davidson; Eleftherios Mamounas; Jo Anne Zujewski; Norman Wolmark
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

5.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Authors:  Luca Gianni; Tadeusz Pienkowski; Young-Hyuck Im; Laslo Roman; Ling-Ming Tseng; Mei-Ching Liu; Ana Lluch; Elżbieta Staroslawska; Juan de la Haba-Rodriguez; Seock-Ah Im; Jose Luiz Pedrini; Brigitte Poirier; Paolo Morandi; Vladimir Semiglazov; Vichien Srimuninnimit; Giulia Bianchi; Tania Szado; Jayantha Ratnayake; Graham Ross; Pinuccia Valagussa
Journal:  Lancet Oncol       Date:  2011-12-06       Impact factor: 41.316

6.  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer.

Authors:  Gunter von Minckwitz; Marion Procter; Evandro de Azambuja; Dimitrios Zardavas; Mark Benyunes; Giuseppe Viale; Thomas Suter; Amal Arahmani; Nathalie Rouchet; Emma Clark; Adam Knott; Istvan Lang; Christelle Levy; Denise A Yardley; Jose Bines; Richard D Gelber; Martine Piccart; Jose Baselga
Journal:  N Engl J Med       Date:  2017-06-05       Impact factor: 91.245

7.  Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

Authors:  Sandra M Swain; José Baselga; Sung-Bae Kim; Jungsil Ro; Vladimir Semiglazov; Mario Campone; Eva Ciruelos; Jean-Marc Ferrero; Andreas Schneeweiss; Sarah Heeson; Emma Clark; Graham Ross; Mark C Benyunes; Javier Cortés
Journal:  N Engl J Med       Date:  2015-02-19       Impact factor: 91.245

8.  CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.

Authors:  José Baselga; Sandra M Swain
Journal:  Clin Breast Cancer       Date:  2010-12-01       Impact factor: 3.225

9.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

Authors:  A Schneeweiss; S Chia; T Hickish; V Harvey; A Eniu; R Hegg; C Tausch; J H Seo; Y-F Tsai; J Ratnayake; V McNally; G Ross; J Cortés
Journal:  Ann Oncol       Date:  2013-05-22       Impact factor: 32.976

10.  Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.

Authors:  Edward H Romond; Jong-Hyeon Jeong; Priya Rastogi; Sandra M Swain; Charles E Geyer; Michael S Ewer; Vikas Rathi; Louis Fehrenbacher; Adam Brufsky; Catherine A Azar; Patrick J Flynn; John L Zapas; Jonathan Polikoff; Howard M Gross; David D Biggs; James N Atkins; Elizabeth Tan-Chiu; Ping Zheng; Greg Yothers; Eleftherios P Mamounas; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-09-17       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.